Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes

NCT02240030 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

351

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Parkinson's Disease

Interventions

DRUG: CVT-301 Low Dose
DRUG: CVT-301 High Dose
OTHER: Placebo

Sponsor

Acorda Therapeutics